VCYT · Veracyte, Inc.

Current Thesis

Veracyte is a profitable precision-oncology diagnostics compounder that has now stacked three favorable catalysts in five weeks and a fourth growth leg has quietly opened. The Q1 2026 beat-and-raise (2026-05-05), the ASCO OPTIMA + ENZAMET datasets (2026-05-30), and the TrueMRD Medicare coverage win (announced 2026-05-15, commercial launch 2026-06-01) together carried the stock +40% in a month to ~$49–50, the very top of its 52-week range ($22.61–$50.71). The fundamentals are genuinely ACCELERATING; the tape is MATURING. Every hard binary has already fired favorably, sell-side is upgrading after the move (Needham → $57 on 2026-06-01), consensus PT (~$45) sits below spot, and the CFO sold into the high (2026-06-04). This is a quality name at poor fresh-entry geometry strength to respect, not chase blind at the high.

Bull Case

• Q1 2026 beat-and-raise (2026-05-05): Revenue $139.1M (+21% YoY) vs consensus ~$130.4M; GAAP net income $28.7M; adjusted EBITDA $42.8M; EPS $0.52 vs consensus ~$0.31 (≈+68% beat). Profitable double-digit grower, a rarity in diagnostics.
• FY26 guidance raised (2026-05-05): Total revenue lifted to $582–592M (13–14% growth) from $570–582M; adjusted EBITDA margin to >26%. Beat and raise.
• Decipher prostate is the engine: Q1 Decipher revenue $86.5M, +30% YoY fastest-growing line and core moat; ENZAMET (ASCO 2026-05-30) added Level 1B evidence for using the genomic test to guide triplet-therapy decisions, supporting guideline inclusion and reimbursement.
• OPTIMA breast data (ASCO 2026-05-30): independent UCL trial showed Prosigna can identify ~68% of clinically high-risk early-stage ER+/HER2- patients who can safely skip adjuvant chemo; full U.S. commercial availability begins 2026-06-08.
• New franchise TrueMRD (Medicare coverage 2026-05-15, launched 2026-06-01): Veracyte's first molecular-residual-disease offering and the only commercially available whole-genome MRD test. Pivotal European Urology study (112 muscle-invasive bladder cancer patients, >900 samples) detected recurrence a median of 131 days earlier than imaging. Shares popped +5.4% on the coverage news. MRD monitoring is a recurring-revenue TAM that did not exist in the model a quarter ago.
• Sell-side ratcheting up: Needham Buy $57 (2026-06-01, raised from $48); Wolfe Research initiated Outperform $55; Jefferies Buy $45.

Bear Case

• Entry is extended: +40% over one month, hitting $49.94 on 2026-06-04, parked at the top of the 52-week range. Buying here means paying for post-catalyst strength with no base underneath.
• Every binary already fired: Q1 print, and the MRD coverage are all in the rearview. The pre-catalyst asymmetry this playbook hunts is spent; the next hard binary (Q2 print) is ~early August, outside any near-term window.
• Insider selling into the high: CFO Rebecca Chambers sold 3,561 shares at an average $49.73 on 2026-06-04 (Form 4) distribution at the 52-week high. Routine or not, it is supply at the exact level a fresh buyer would chase.
• Sell-side is the late tell: consensus PT ~$45 sits below spot; Canaccord stays Hold at $42 (below market). Only the top two bulls (Needham $57, Wolfe $55) sit above price thin headroom to the crowd.
• Valuation stretched: ~$3.9B market cap, ~mid-20s× EBITDA on a 13–14% topline grower. Real fundamentals, full multiple.
• High beta (1.54): an XBI/IBB risk-off leg amplifies the drawdown here; this is not a defensive holding.
• LDT regulatory overhang: FDA lab-developed-test rule litigation is a sector tail that would hit the whole diagnostics group at once.

Setup & Price Structure

• Spot ~$49.13–$49.94 (2026-06-04); intraday range that session $48.70–$50.54. 52-week range $22.61–$50.71 pinned at the very top, a fresh-high tape.
• Momentum: +40% over one month, ~+18% since the 2026-05-05 print. Beta 1.54. Market cap ~$3.92B.
• Structure: post-earnings breakout/retest base sits ~$40–44; the rising weekly 20-EMA is estimated ~$43–44; the 200-day is well below in the low-$30s. Price is stretched above all moving averages post-event extension.
• Read: a decisive break-and-hold above the $50.71 52-week high on expanding volume is the continuation confirmation; failure to hold the $46–47 shelf is the first crack. The clean re-entry geometry is a pullback to the $42–44 breakout retest holding as a higher low that base has not been tested since the run.

Catalyst Calendar (next 30 days)

• 2026-06-08: Prosigna Breast Risk of Recurrence test reaches full U.S. commercial availability a rollout milestone, not a binary print.
• 2026-06-01 (just passed): TrueMRD MIBC test live for ordering early ordering/volume color is the thing to watch into the Q2 call.
• Ongoing (weeks): payer and guideline-body responses to the OPTIMA breast and ENZAMET prostate ASCO datasets; any NCCN/reimbursement movement is an incremental driver.
• No hard binary inside the window. Q2 2026 earnings expected ~early August 2026 (est.) outside 30 days; treat it as the next true catalyst and avoid fresh entries within three trading days of the confirmed date.

What Would Change Our Mind

• Bullish re-accelerant: a weekly break-and-hold above $50.71 on expanding volume, paired with early evidence of MRD ordering traction, would mark a fresh ACCELERATING leg and justify a re-rate above the current crowd.
• Bearish thesis-break: a weekly close below the rising 20-EMA / breakout retest (~$43), or Q2 testing-revenue growth decelerating below +20% YoY (vs +26% in Q1) or Decipher prostate below +20% (vs +30%).
• Saturation flip: sell-side fully converging to spot with no further estimate revisions while the MRD launch fails to add a measurable new growth vector at that point the theme reads SATURATED and the right move is to stand aside until it bases.

Correlation Notes

• MRD competitive frame: the TrueMRD launch puts VCYT directly alongside Natera (NTRA, Signatera) and Guardant (GH, Reveal) in molecular-residual-disease. Peer MRD data prints and coverage decisions now move VCYT sentiment; watch NTRA/GH for read-through.
• Precision-oncology dx cluster: Exact Sciences (EXAS), Natera (NTRA), Guardant (GH) trade as a group shared narrative, shared multiple compression risk.
• Sector beta: high beta (1.54) ties VCYT to XBI/IBB; a biotech risk-off leg amplifies here despite the profitability.
• Rate sensitivity is muted relative to peers: VCYT is profitable (Q1 adj EBITDA $42.8M), so it carries less duration risk than pre-revenue diagnostics names, but it still re-rates with the group multiple.
• LDT regulatory tail is correlated: a single FDA or court ruling on lab-developed tests would hit EXAS, NTRA, and VCYT simultaneously a cluster risk, not an idiosyncratic one.